RS65611B1 - Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida - Google Patents

Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida

Info

Publication number
RS65611B1
RS65611B1 RS20240598A RSP20240598A RS65611B1 RS 65611 B1 RS65611 B1 RS 65611B1 RS 20240598 A RS20240598 A RS 20240598A RS P20240598 A RSP20240598 A RS P20240598A RS 65611 B1 RS65611 B1 RS 65611B1
Authority
RS
Serbia
Prior art keywords
polymorph
dihydro
inden
ethyl
methyl
Prior art date
Application number
RS20240598A
Other languages
English (en)
Serbian (sr)
Inventor
Norma TOM
Matthew Pfeiffer
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS65611(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of RS65611B1 publication Critical patent/RS65611B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20240598A 2019-07-17 2020-07-16 Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida RS65611B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
EP20753562.6A EP3999180B1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
RS65611B1 true RS65611B1 (sr) 2024-07-31

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240598A RS65611B1 (sr) 2019-07-17 2020-07-16 Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida

Country Status (25)

Country Link
US (1) US20220315571A1 (https=)
EP (2) EP3999180B1 (https=)
JP (2) JP7624431B2 (https=)
KR (1) KR20220084008A (https=)
CN (3) CN114555590B (https=)
AU (1) AU2020313965A1 (https=)
BR (1) BR112022000494A2 (https=)
CA (1) CA3144975A1 (https=)
CL (1) CL2022000054A1 (https=)
DK (1) DK3999180T3 (https=)
ES (1) ES2980885T3 (https=)
FI (1) FI3999180T3 (https=)
HR (1) HRP20240713T1 (https=)
HU (1) HUE066891T2 (https=)
IL (1) IL289875A (https=)
LT (1) LT3999180T (https=)
MX (1) MX2022000504A (https=)
PH (1) PH12022550123A1 (https=)
PL (1) PL3999180T3 (https=)
PT (1) PT3999180T (https=)
RS (1) RS65611B1 (https=)
SI (1) SI3999180T1 (https=)
SM (1) SMT202400224T1 (https=)
TW (1) TWI865562B (https=)
WO (1) WO2021011807A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
MX2024001294A (es) 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
EP4565230A1 (en) 2022-08-04 2025-06-11 Cytokinetics, Inc. Methods for treating obstructive hypertrophic cardiomyopathy
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
US20250295639A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
MX2024001294A (es) * 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.

Also Published As

Publication number Publication date
CA3144975A1 (en) 2021-01-21
IL289875A (en) 2022-03-01
CN118908951A (zh) 2024-11-08
EP3999180B1 (en) 2024-05-08
PL3999180T3 (pl) 2024-09-23
NZ784930A (en) 2025-03-28
SMT202400224T1 (it) 2024-07-09
JP2022540668A (ja) 2022-09-16
DK3999180T3 (da) 2024-05-21
HRP20240713T1 (hr) 2024-09-13
JP2025061484A (ja) 2025-04-10
JP7624431B2 (ja) 2025-01-30
EP4487911A1 (en) 2025-01-08
ES2980885T3 (es) 2024-10-03
AU2020313965A1 (en) 2022-03-03
LT3999180T (lt) 2024-08-26
US20220315571A1 (en) 2022-10-06
WO2021011807A1 (en) 2021-01-21
SI3999180T1 (sl) 2024-07-31
HUE066891T2 (hu) 2024-09-28
KR20220084008A (ko) 2022-06-21
FI3999180T3 (fi) 2024-06-18
TWI865562B (zh) 2024-12-11
CN114555590B (zh) 2024-09-10
CN114555590A (zh) 2022-05-27
CL2022000054A1 (es) 2022-10-07
TW202116763A (zh) 2021-05-01
PH12022550123A1 (en) 2022-12-19
EP3999180A1 (en) 2022-05-25
JP7755090B2 (ja) 2025-10-15
BR112022000494A2 (pt) 2022-03-03
PT3999180T (pt) 2024-06-25
MX2022000504A (es) 2022-02-10
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
RS65611B1 (sr) Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida
EP3999181B1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
JP5178526B2 (ja) 化合物、組成物および方法
US20240132498A1 (en) Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40121580A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40111816A (zh) 多晶型物
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40125944A (zh) 5-(3，4-二氟苄基)-8-((1r，4r)-4-甲基环己基)-6，9-二氧代基-2，5，8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
JP2013184934A (ja) オキサジアゾリジンジオン化合物の新規な塩及びその結晶